Perrigo Company PLC
PRGO15.065USD
+0.125+0.84%
Fechamento 01/13, 16:00（ET）Cotações atrasadas em 15 min
2.07BValor de mercado
PerdaP/L TTM
Mais detalhes de Perrigo Company PLC Empresa
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
Informações de Perrigo Company PLC
Código da empresaPRGO
Nome da EmpresaPerrigo Company PLC
Data de listagemDec 17, 1991
CEOLockwood-Taylor (Patrick)
Número de funcionários8379
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 17
EndereçoThe Sharp Building
CidadeDUBLIN
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísIreland
Código postalD02 TY74
Telefone3532696738451
Sitehttps://www.perrigo.com/
Código da empresaPRGO
Data de listagemDec 17, 1991
CEOLockwood-Taylor (Patrick)
Executivos da empresa Perrigo Company PLC
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Patrick Lockwood-Taylor
Mr. Patrick Lockwood-Taylor
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
85.81K
+4460.00%
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Independent Director
Independent Director
60.29K
+8650.00%
Mr. Eduardo Guarita Bezerra
Mr. Eduardo Guarita Bezerra
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
48.95K
+3000.00%
Mr. Robert Willis
Mr. Robert Willis
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
41.94K
+1488.00%
Mr. Bradley A. (Brad) Alford
Mr. Bradley A. (Brad) Alford
Independent Director
Independent Director
41.16K
+5150.00%
Mr. Donal O'Connor
Mr. Donal O'Connor
Independent Director
Independent Director
31.84K
+5150.00%
Ms. Adriana (Andi) Karaboutis
Ms. Adriana (Andi) Karaboutis
Independent Director
Independent Director
27.63K
+5150.00%
Mr. Orlando D. Ashford
Mr. Orlando D. Ashford
Independent Chairman of the Board
Independent Chairman of the Board
22.17K
+6437.00%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
10.56K
+5150.00%
Ms. Julia M. Brown
Ms. Julia M. Brown
Independent Director
Independent Director
8.03K
+5150.00%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Patrick Lockwood-Taylor
Mr. Patrick Lockwood-Taylor
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
85.81K
+4460.00%
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Independent Director
Independent Director
60.29K
+8650.00%
Mr. Eduardo Guarita Bezerra
Mr. Eduardo Guarita Bezerra
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
48.95K
+3000.00%
Mr. Robert Willis
Mr. Robert Willis
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
41.94K
+1488.00%
Mr. Bradley A. (Brad) Alford
Mr. Bradley A. (Brad) Alford
Independent Director
Independent Director
41.16K
+5150.00%
Mr. Donal O'Connor
Mr. Donal O'Connor
Independent Director
Independent Director
31.84K
+5150.00%
Detalhamento da receita
Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Upper respiratory
182.00M
17.44%
Pain and sleep-aids
169.20M
16.22%
Skincare and personal hygiene
150.60M
14.43%
Healthy lifestyle
133.80M
12.82%
Digestive health
116.10M
11.13%
Outro
291.60M
27.95%
Por RegiãoUSD
Nome
Receita
Proporção
United States
635.30M
60.89%
Europe
384.00M
36.81%
All other countries
24.00M
2.30%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Upper respiratory
182.00M
17.44%
Pain and sleep-aids
169.20M
16.22%
Skincare and personal hygiene
150.60M
14.43%
Healthy lifestyle
133.80M
12.82%
Digestive health
116.10M
11.13%
Outro
291.60M
27.95%
Distribuição de ações
Atualizado em: qui, 8 de jan
Atualizado em: qui, 8 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
T. Rowe Price Associates, Inc.
12.20%
The Vanguard Group, Inc.
10.04%
BlackRock Institutional Trust Company, N.A.
8.70%
Dimensional Fund Advisors, L.P.
5.59%
State Street Investment Management (US)
5.02%
Outro
58.46%
Investidores
Investidores
Proporção
T. Rowe Price Associates, Inc.
12.20%
The Vanguard Group, Inc.
10.04%
BlackRock Institutional Trust Company, N.A.
8.70%
Dimensional Fund Advisors, L.P.
5.59%
State Street Investment Management (US)
5.02%
Outro
58.46%
Tipos de investidores
Investidores
Proporção
Investment Advisor
64.13%
Investment Advisor/Hedge Fund
37.62%
Hedge Fund
5.32%
Research Firm
2.06%
Pension Fund
1.58%
Sovereign Wealth Fund
1.12%
Bank and Trust
0.47%
Individual Investor
0.44%
Insurance Company
0.06%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
757
155.20M
112.77%
-15.97M
2025Q3
771
148.06M
107.58%
-20.94M
2025Q2
791
145.85M
106.01%
-21.49M
2025Q1
812
142.34M
103.61%
-25.15M
2024Q4
806
140.28M
102.80%
-22.73M
2024Q3
798
138.34M
101.41%
-20.68M
2024Q2
800
136.29M
99.93%
-16.34M
2024Q1
799
135.97M
99.77%
-20.56M
2023Q4
809
135.31M
99.86%
-23.17M
2023Q3
797
133.80M
98.82%
-17.47M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
T. Rowe Price Associates, Inc.
16.79M
12.2%
+2.36M
+16.34%
Sep 30, 2025
The Vanguard Group, Inc.
13.82M
10.04%
-144.87K
-1.04%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
11.97M
8.7%
+209.84K
+1.78%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
7.70M
5.59%
+181.83K
+2.42%
Sep 30, 2025
State Street Investment Management (US)
6.90M
5.02%
-437.33K
-5.96%
Sep 30, 2025
Neuberger Berman, LLC
5.73M
4.16%
+2.02M
+54.36%
Sep 30, 2025
Cooke & Bieler, L.P.
3.68M
2.67%
+381.29K
+11.56%
Sep 30, 2025
Sound Shore Management, Inc.
3.65M
2.65%
+363.33K
+11.05%
Sep 30, 2025
Thompson, Siegel & Walmsley LLC
3.63M
2.64%
+1.30M
+56.12%
Sep 30, 2025
DePrince, Race & Zollo, Inc.
3.54M
2.57%
-1.03M
-22.50%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Sound Equity Dividend Income ETF
3.3%
State Street SPDR S&P Pharmaceuticals ETF
2.44%
Invesco Pharmaceuticals ETF
2.34%
AAM Bahl & Gaynor Small/Mid Cap Income Growth ETF
1.54%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.35%
ProShares S&P MidCap 400 Dividend Aristocrats ETF
1.32%
First Trust Health Care Alphadex Fund
1.22%
Invesco S&P MidCap 400 Pure Value ETF
1.19%
Invesco High Yield Equity Dividend Achievers ETF
1.11%
iShares U.S. Pharmaceuticals ETF
1.05%
Ver Mais
Sound Equity Dividend Income ETF
Proporção3.3%
State Street SPDR S&P Pharmaceuticals ETF
Proporção2.44%
Invesco Pharmaceuticals ETF
Proporção2.34%
AAM Bahl & Gaynor Small/Mid Cap Income Growth ETF
Proporção1.54%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção1.35%
ProShares S&P MidCap 400 Dividend Aristocrats ETF
Proporção1.32%
First Trust Health Care Alphadex Fund
Proporção1.22%
Invesco S&P MidCap 400 Pure Value ETF
Proporção1.19%
Invesco High Yield Equity Dividend Achievers ETF
Proporção1.11%
iShares U.S. Pharmaceuticals ETF
Proporção1.05%
Dividendo
Um total de
574.20M
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Oct 29, 2025
PRGO.NB Final Cash Dividend of gross USD 0.29 paid on Dec 16, 2025 going ex on Nov 28, 2025
Nov 28, 2025
Dec 16, 2025
Nov 28, 2025
Jul 30, 2025
PRGO.NB Interim Cash Dividend of gross USD 0.29 paid on Sep 16, 2025 going ex on Aug 29, 2025
Aug 29, 2025
Sep 16, 2025
Aug 29, 2025
Apr 30, 2025
PRGO.NB Interim Cash Dividend of gross USD 0.29 paid on Jun 17, 2025 going ex on May 30, 2025
May 30, 2025
Jun 17, 2025
May 30, 2025
Feb 19, 2025
PRGO.NB Interim Cash Dividend of gross USD 0.29 paid on Mar 25, 2025 going ex on Mar 07, 2025
Mar 07, 2025
Mar 25, 2025
Mar 07, 2025
Nov 01, 2024
PRGO.NB Final Cash Dividend of gross USD 0.276 paid on Dec 17, 2024 going ex on Nov 29, 2024
Nov 29, 2024
Dec 17, 2024
Nov 29, 2024
Aug 01, 2024
PRGO.NB Interim Cash Dividend of gross USD 0.276 paid on Sep 17, 2024 going ex on Aug 30, 2024
Aug 30, 2024
Sep 17, 2024
Aug 30, 2024
May 01, 2024
PRGO.NB Interim Cash Dividend of gross USD 0.276 paid on Jun 18, 2024 going ex on May 31, 2024
May 31, 2024
Jun 18, 2024
May 31, 2024
Feb 26, 2024
PRGO.NB Interim Cash Dividend of gross USD 1.1 paid on Mar 26, 2024 going ex on Mar 07, 2024
Mar 08, 2024
Mar 26, 2024
Mar 07, 2024
Nov 03, 2023
PRGO.NB Final Cash Dividend of gross USD 0.273 paid on Dec 19, 2023 going ex on Nov 30, 2023
Dec 01, 2023
Dec 19, 2023
Nov 30, 2023
Aug 02, 2023
PRGO.NB Interim Cash Dividend of gross USD 0.273 paid on Sep 19, 2023 going ex on Aug 31, 2023
Sep 01, 2023
Sep 19, 2023
Aug 31, 2023
Ver Mais
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
Perguntas frequentes
Quem são os cinco principais acionistas de Perrigo Company PLC?
Os cinco principais acionistas de Perrigo Company PLC são:
T. Rowe Price Associates, Inc. detém 16.79M Ações, representando 12.20% do total de Ações.
The Vanguard Group, Inc. detém 13.82M Ações, representando 10.04% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 11.97M Ações, representando 8.70% do total de Ações.
Dimensional Fund Advisors, L.P. detém 7.70M Ações, representando 5.59% do total de Ações.
State Street Investment Management (US) detém 6.90M Ações, representando 5.02% do total de Ações.
T. Rowe Price Associates, Inc. detém 16.79M Ações, representando 12.20% do total de Ações.
The Vanguard Group, Inc. detém 13.82M Ações, representando 10.04% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 11.97M Ações, representando 8.70% do total de Ações.
Dimensional Fund Advisors, L.P. detém 7.70M Ações, representando 5.59% do total de Ações.
State Street Investment Management (US) detém 6.90M Ações, representando 5.02% do total de Ações.
Quais são os três principais tipos de acionistas de Perrigo Company PLC?
Os três principais tipos de acionistas da Perrigo Company PLC são:
T. Rowe Price Associates, Inc.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
T. Rowe Price Associates, Inc.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Quantas instituições possuem ações da Perrigo Company PLC (PRGO)?
Em 2025Q4, 757 instituições possuíam ações da Perrigo Company PLC, com valor de mercado aproximado de 155.20M, representando 112.77% do total de ações. Em comparação com 2025Q3, a participação institucional aumentou em 5.19%.
Qual é a maior fonte de receita da Perrigo Company PLC?
Em FY2025Q3, o segmento de negócios Upper respiratory gerou a maior receita para Perrigo Company PLC, totalizando 182.00M e representando 17.44% da receita total.
